Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Key Takeaways Real-world results with weight-loss drugs aren’t as impressive as those in clinical trialsClinic patients ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

"This study allowed us to do a direct comparison ... "Across the respective clinical trial programs and in SURMOUNT-5, both Wegovy and Zepbound have demonstrated clinically significant weight ...

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

All received weekly injections of the highest medication dose they could tolerate — up to 10 or 15 milligrams (mg) of Zepbound or 1.7 or 2.4 mg of Wegovy. By the end of the study, people on the ...